These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 30644678)

  • 1. [Treatment with new, long-acting antipsychotic drugs without informed consent].
    Skui H; Hellevik V; Hovdal TT; Valle AL
    Tidsskr Nor Laegeforen; 2019 Jan; 139(1):. PubMed ID: 30644678
    [No Abstract]   [Full Text] [Related]  

  • 2. Italian Law no. 219/2017: consequences on the informed consent of the psychiatric patient and on the therapeutic privilege.
    Cioffi A; Zaami S
    Riv Psichiatr; 2020; 55(2):129-130. PubMed ID: 32202551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presumed dangerous: California's selective policy of forcibly medicating state prisoners with antipsychotic drugs.
    Gross DE
    Univ Calif Davis Law Rev; 2002 Jan; 35():483-517. PubMed ID: 17066562
    [No Abstract]   [Full Text] [Related]  

  • 4. [Psychotic patients are denied treatment on a voluntary basis].
    Gjerden P
    Tidsskr Nor Laegeforen; 2019 Feb; 139(3):. PubMed ID: 30754953
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-acting injectable antipsychotics in early psychosis: a literature review.
    Emsley R; Chiliza B; Asmal L; Mashile M; Fusar-Poli P
    Early Interv Psychiatry; 2013 Aug; 7(3):247-54. PubMed ID: 23342964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Could Psychiatry Dispense with Involuntary Medication? - Pro].
    Zinkler M; Koussemou JM
    Psychiatr Prax; 2016 May; 43(4):187-8. PubMed ID: 27145350
    [No Abstract]   [Full Text] [Related]  

  • 7. [Could Psychiatry Dispense with Involuntary Medication? - Contra].
    Noorthoorn E
    Psychiatr Prax; 2016 May; 43(4):189-90. PubMed ID: 27145351
    [No Abstract]   [Full Text] [Related]  

  • 8. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Position of Canadian psychiatry].
    Stip E
    Encephale; 2009 Jan; Suppl 3():S115-8. PubMed ID: 19268180
    [No Abstract]   [Full Text] [Related]  

  • 9. Concealed medicines for people with schizophrenia: a U.S. perspective.
    Stroup S; Swartz M; Appelbaum P
    Schizophr Bull; 2002; 28(3):537-42. PubMed ID: 12645685
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical guideline recommendations for antipsychotic long-acting injections.
    Kane JM; Garcia-Ribera C
    Br J Psychiatry Suppl; 2009 Nov; 52():S63-7. PubMed ID: 19880920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia.
    Rosenheck RA; Krystal JH; Lew R; Barnett PG; Thwin SS; Fiore L; Valley D; Huang GD; Neal C; Vertrees JE; Liang MH;
    Clin Trials; 2011 Apr; 8(2):196-204. PubMed ID: 21270143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The problem of coercion.
    Jacobsen GW
    Tidsskr Nor Laegeforen; 2017 Nov; 137(22):. PubMed ID: 29181906
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics.
    Chue P; Emsley R
    CNS Drugs; 2007; 21(6):441-8. PubMed ID: 17521224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restrict the Recruitment of Involuntarily Committed Patients for Psychiatric Research.
    Elliott C; Lamkin M
    JAMA Psychiatry; 2016 Apr; 73(4):317-8. PubMed ID: 26864804
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of long-acting risperidone.
    Pinninti NR; Mago R
    Psychiatr Serv; 2005 Jan; 56(1):105; author reply 106-7. PubMed ID: 15637204
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of long-acting risperidone.
    Parker G
    Psychiatr Serv; 2005 Jan; 56(1):105-6; author reply 106-7. PubMed ID: 15637203
    [No Abstract]   [Full Text] [Related]  

  • 17. [Judges confirm the fundamental right to physical integrity].
    Weber M
    Pflege Z; 2012 Oct; 65(10):626-8. PubMed ID: 23098036
    [No Abstract]   [Full Text] [Related]  

  • 18. Financial incentives for antipsychotic depot medication: ethical issues.
    Claassen D
    J Med Ethics; 2007 Apr; 33(4):189-93. PubMed ID: 17400613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of institutionalized mental health patients' right to refuse psychotropic drugs.
    Kemna DJ
    J Leg Med; 1985 Mar; 6(1):107-38. PubMed ID: 2860193
    [No Abstract]   [Full Text] [Related]  

  • 20. The use of depot medications in the treatment of schizophrenia.
    Davis JM
    Am J Psychiatry; 2010 Feb; 167(2):125-6. PubMed ID: 20123919
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.